Retatrutide Achieves 28.7% Weight Loss and Knee Pain Reduction in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.